The Aims of the Scientific Steering Committee
To provide scientific direction and monitor the integrity of the research within the Centre.
To facilitate effective communication and collaboration between the partners to maximise and sustain research performance.
To review all research for the potential for commercialisation.
Dr Carl Goodyear
Director, GLAZgo Discovery Centre
Senior Lecturer, Institute of Infection, Immunity and Inflammation
University of Glasgow
Dr Carl Goodyear studied at the University of Glasgow and Glasgow Caledonian University, gaining a BSc with honours in Molecular Biology in 1996 and a PhD in Molecular Immunology in 1999. Upon completing his PhD, Dr Goodyear moved to the US and worked in the Department of Medicine at the University of California at San Diego where he held the position of Assistant Professor. During this period Dr Goodyear was awarded a Cancer Research Institute Postdoctoral Fellowship, became a National Blood Foundation Scholar, and received a number of awards including the National Blood Foundation David B. Pall Prize for Innovative Research in Transfusion Medicine and an Arthritis Foundation Investigator Award. In 2006 he returned to work in the UK at the Institute of Infection Immunity and Inflammation in the University of Glasgow. He was awarded a prestigious Arthritis Research UK Fellowship and shortly after became a Senior Lecturer. Dr Goodyear’s research has continued to gain awards such as the Inaugural Medical Research Scotland Vipiana Award.
Dr Goodyear’s research group is currently focused on understanding immunopathogenesis of disease (i.e., Rheumatoid Arthritis, Osteoarthritis & Multiple Myeloma) and translating this knowledge into viable therapeutic agents for patients. In parallel, Dr. Goodyear also leads a Translational Immunology programme, which provides the critical interface between clinical and basic science.
Professor Iain B McInnes
Muirhead Chair of Medicine & Director of Institute
Institute of Infection, Immunity and Inflammation
University of Glasgow
Professor Iain McInnes studied medicine at the University of Glasgow and graduated with honours in 1989 before training in internal medicine and rheumatology. He completed his membership of the Royal College of Physicians (MRCP) in 1992 and became a fellow (FRCP) in 2003. He completed his PhD and post-doctoral studies via fellowships from the Wellcome Trust, the Arthritis Research Campaign (ARC, UK) and the National Institute of Health (NIH) Fogarty Fellowship Programme in both Glasgow and Bethesda, Maryland, USA.
Professor McInnes’ research interests include understanding the role of cytokines in inflammatory synovitis. He leads a trials unit specialising in the use of biologic agents in early clinical trials in inflammatory arthritis. Professor McInnes has published widely in the areas of immunobiology and rheumatology, and is an Associate Editor of the Annals of Rheumatic Diseases and a member of the executive Editorial Board of European Journal of Immunology. His work, together with that of his colleagues at the University of Glasgow, has been recognised in receipt of many prizes and lectureships including the Michael Mason Prize 2001 from the British Society for Rheumatology, the Albrecht Hasinger Lectureship 2002, the Nana Svartz Lectureship 2008, and the Dunlop Dotteridge Lectureship for the Canadian Rheumatology Association in 2010. He gave the BSR Droitwich Lecture in 2012, and the Gerald Weissmann Lecture in Rheumatology in New York in 2013. A previous Chairman of the EULAR Scientific Committee and ESCCA, he is now Chairman of the Scientific Committee of the European Rheumatology Research Foundation. He was elected a fellow of the Royal Society of Edinburgh in 2008 and in 2012 was elected as a Fellow of the Academy of Medical Sciences.
Professor Graeme Milligan
Gardiner Professor of Biochemistry and
Professor of Molecular Pharmacology
Institute of Molecular, Cell and Systems Biology
University of Glasgow
Professor Milligan studied biochemistry at University of Birmingham and following a Ph.D. in neuropharmacology at University of Nottingham then moved to the National Institutes of Health in Bethesda MD as a Fogarty International Visiting Fellow. During this period he developed a research programme on the molecular basis of opioid receptor signalling. Analysis of the molecular mechanisms of signal transduction by G protein-coupled receptors (GPCRs) has remained a central component of his research until the present day. He moved to Glasgow University in 1986 to a position at the interface of pharmacology and biochemistry. Currently his ‘GPCR’ research team is divided into two broad themes: The first of these studies the quaternary organisation of GPCRs into dimers and higher-order complexes and the implications of this for both function and the opportunities this might provide for novel therapeutic drug design. These studies incorporate approaches that range from basic pharmacology and homology modelling to mathematics and biophysics. The second theme of his work is focused on the validation and therapeutic translation of GPCRs that respond to circulating metabolites, including both short- and longer-chain free fatty acids, and centres currently on treatments for diabetes, obesity and inflammatory conditions of the lower gut. Herein, medicinal chemistry programmes align with novel animal models to provide unique insight. Professor Milligan holds a longstanding interest in developing novel technologies to enhance and improve early stage drug discovery and has licensed a number of such approaches to the pharmaceutical industry . He was elected to the Fellowship of the Royal Society of Edinburgh in 1998 and awarded the ‘Ariens’ prize for pharmacology in 2006. He is a Thompson Reuter 2014 Highly Cited Researcher (http://highlycited.com) a recognition of researchers with the greatest number of ‘highly cited’ (i.e. within the top 1% of citations after mitigation in a field specific manner) papers over the period 2002-2012.
Professor Gerard Graham
Professor of Molecular and Structural Immunology in the Institute of Infection, Immunity & Inflammation
Professor Graham is the Head of the Chemokine Research Group and Deputy Director of the Institute of Infection, Immunity & Inflammation. His research is mainly funded by a Programme grant from the Medical Research Council as well as by a Wellcome Trust Senior Investigator Award. His group is one of the largest chemokine research groups in the world and he has published widely in this important area. Professor Graham served on the MRC Infections and Immunity Board for four years and is currently Chair of the Wellcome Trust Expert Review Group on the Immune System in Health and Disease. Professor Graham is a Fellow of the Royal Society of Edinburgh and holds a Wolfson-Royal Society Research merit award.
Professor Rose Maciewicz
Chief Scientist (Honorary Professor University of Manchester)
Respiratory, Inflammation, Autoimmunity Abed, AstraZeneca, Cambridge
Rose Maciewicz studied at the University of Buffalo graduating with a BA in Biology (Summa Cum Laude) in 1976, and a MA (1978) / PhD (1980) in Cell and Molecular Biology. Upon completing her PhD, on in vivo hormonal induced gene activation, she undertook a Post Doctoral Research Associate position at The Johns Hopkins University, Department of Biology, Baltimore, Maryland where she investigated the structure-function relationship of gene activation at the nucleosomal level. Moving to the UK she did further postdoctoral work on cysteine and metalloproteinases in disease which was funded by the Arthritis Research Council as well as collaborated on projects funded by the Cancer Research UK. She undertook a sabbatical as a group leader at a biotech company (Prototek) in California before she joined AstraZeneca (legacy companies ICI, Zeneca). At AstraZeneca she has held various leadership positions (science, project and management). She has in-depth experience in research and early development across a broad range of diseases including musculo-skeletal, cardiovascular and respiratory diseases. Projects she initiated in the osteoarthritis area are currently in early clinical development. Externally she has been an committee members for taskforces / steering groups that have set the future agenda in osteoarthritis, as well as private public partnerships in regenerative medicine (Regener8) and stem cells in drug discovery (SC4SM). She has been an external advisor for orthopeadic companies. A previous committee member and Secretary of the British Society for Matrix Biology, she currently sits on the Scientific Advisory Board for Arthritis UK Pain Centre, the Board of Directors for the Manchester Collaborative Centre for Inflammation Research (MCCIR) and the White Rose University Centre doctoral training program funded by the BBSRC. She has established and leads a highly-regarded internal postdoctoral programme in AstraZeneca that currently supports 100 post-docs. She has organised major external conferences (Lund COPD Symposium). She collaborates widely with the external academic community and has published extensively.
Professor Paul Garside
Chair of Basic Immunology
Institute of Infection, Immunity & Inflammation, University of Glasgow